Sanofi raises 2026 sales growth outlook to low-teens, eyes larger M&A

Sanofi raised its 2026 sales growth forecast to a low-teens percentage, up from a previous outlook of 10%, driven by strong demand for its asthma drug Dupixent. The company also anticipates larger M&A activity.

Detected & updated continuously · Source: Nebula